產(chǎn)品編號 | 506069 |
品牌 | Sigma |
測定 | ≥98% (HPLC) |
警告 | Toxicity: Standard Handling (A) |
形式 | liquid |
分子量 | 407.68 |
質(zhì)量水平 | 100 |
儲存溫度 | ?70°C |
別名
InSolution EZH2 Inhibitor, DZNep - CAS 102052-95-9 - Calbiochem,3-Deazaneplanocin A, xHCl, yH?O {x = 3 & y = 2}, (1S,2R,5R)-5-(4-Amino-1H-imidazo[4,5-c]pyridin-1-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol, xHCl, yH?O {x = 3 & y = 2}, NSC 617989
儲存條件
OK to freeze
avoid repeated freeze/thaw cycles
protect from light
一般描述
A cell-permeable compound that is shown (at 1 μM concentrations) to inhibit EZH2-mediated trimethylation of K27 on histone H3 and induces the expression of cell-cycle regulatory genes, p21 and p27, as well as the cell death regulator, FBXO32, in OCI-AML3 and HL-60 cells, whereby treatment with inhibitor increases p16 levels in the former, but not the latter of the two cultures. At concentrations between 200 nm and 2000 nM, this compound is found to dose-dependently deplete the expression of polycomb group proteins EZH2, SUZ12, and EED in cultured and primary AML cell extracts. At concentrations up to ≥ 1000 nM, DZNep dose-dependently increases the percentage of apoptotic cells up to > ~ 38%, with greater potency against OCI-AML3 than HL-60 cultures and inhibits colony growth up to > ~ 85% for both cell lines. In OCI-AML3 cultures, 1000 nM of treatment demonstrates a significant increase in the accumulation of cells in the G0/G1 phase (58.5%) with a concomitant decrease in the number of cells in S phase (35.2%) and G2/M phases (6.3%) of the cell cycle. When co-treated with panobinostat (PS), 200 nM to 1000nM DZNep is shown to decrease cell viability in OCI-AML3 and HL-60 cultures more effectively than DZNep alone, in a dose-dependent manner. DZNep (1mg/kg, twice per week, i.p.) and PS significantly prolong the survival of mice implanted with HL-60 cells compared to treatment with either compound alone. DZNep is also a known S-adenosyl-L-homocysteine (AdoHcy) hydrolase inhibitor.
生化/生理作用
Cell permeable: yes
Primary Target
EZH2
Reversible: yes
外形
A 25 mM (1 mg/98 μL) sterile-filtered solution of Histone Methyltransferase EZH2 Inhibitor, DZNep (Cat. No. 252790) in H?O.
重懸
Following initial thaw, aliquot and freeze (-20°C). Aliquots are stable for up to 6 monthst at -20°C.
其他說明
Sun, F., et al. 2009. Mol. Cancer Ther.8, 3191.
Miranda, T.B., et al. 2009. Mol. Cancer Ther.8, 1579.
Fiscus, W., et al. 2009. Blood13, 2733.
Tan, J., et al. 2007. Genes Dev.21, 1050.
Chiang, P.K., et al. 1992. J. Biol. Chem.267, 4988.
Tseng, C.K., et al. 1989. J. Med. Chem.32, 1442.
Glazer, R.I., et al. 1986. Biochem. Biophys. Res. Commun.135, 688.
關鍵字: InSolution EZH2 Inhibitor, DZNep - CAS 102052-95-9 - Calbiochem;InSolution EZH2 Inhibitor, DZNep - CAS 102052-95-9 - Calbiochem價格;InSolution EZH2 Inhibitor, DZNep - CAS 102052-95-9 - Calbiochem廠家;102052-95-9;Sigma
關于默克生命科學
我們擁有廣泛的高質(zhì)量產(chǎn)品組合和解決方案,致力于推動科學研究,提高藥物研發(fā)和生物制藥生產(chǎn)的質(zhì)量和效率,并為獲取準確可靠的診斷和檢測結果提供安全的保障。我們的愿景是使全球各地的人們能夠更快地獲得提升人類健康水平的解決方案。我們的共同目標是通過與全球科學界合作,解決生命科學中棘手的問題。
30萬個廣泛產(chǎn)品組合,其中包括業(yè)內(nèi)許多知名的品牌,Sigma-Alrdich?、Milli-Q?、 Supelco?、Millipore?、SAFC?和BioReliance?。
關于默克
是一家全球領先的科技公司,專注于醫(yī)藥健康、生命科學和電子科技三大領域。全球約有57,000名員工服務于默克,通過創(chuàng)造更加愉悅和可持續(xù)性的生活方式,為數(shù)百萬人的生活帶來積極的影響。從先進的基因編輯技術和發(fā)現(xiàn)治療最具挑戰(zhàn)性疾病的獨特方法,到實現(xiàn)設備的智能化——默克無處不在。
科學探索和負責任的企業(yè)精神一直是默克科技進步的關鍵,也是默克自1668年以來永葆活力的秘訣。默克家族作為公司的創(chuàng)始者至今仍持有默克大部分的股份,我們在全球都叫“默克”,僅美國和加拿大例外。默克的三大領域:醫(yī)藥健康、生命科學及電子科技在這兩個國家分別稱之為“EMD Serono”、“MilliporeSigma”和“EMD Electronics”。
默克在中國已經(jīng)有87年發(fā)展歷史,目前有超過4100名員工,在